Abstract Number: 1175 • 2012 ACR/ARHP Annual Meeting
Decreased Frequency of Th17 Cells in Early Rheumatoid Arthritis
Background/Purpose: Our objective was to examine the frequency and phenotype of Th17 cells in the peripheral blood of early RA (eRA) patients. Methods: CD4+ T…Abstract Number: 1136 • 2012 ACR/ARHP Annual Meeting
Aesthetic Dissatisfaction in Hand Osteoarthritis Patients, Its Impact and Risk Factors
Background/Purpose: Hand osteoarthritis (HOA) leads to aesthetic damage and is rarely studied. We aim to investigate in HOA patients the prevalence of dissatisfaction with the…Abstract Number: 1137 • 2012 ACR/ARHP Annual Meeting
Clinimetric Properties of a New Outcome Measure:the Hand-Osteoarthritis Aesthetic Damage Index
Background/Purpose: The 2006 OARSI Guidelines for hand OA clinical trials, recognised the potential value of an aesthetic damage assessment, but acknowledged the absence of any…Abstract Number: 1138 • 2012 ACR/ARHP Annual Meeting
Nonpharmacologic and Pharmacologic Therapy Utilization by Primary Care Providers for Hand Osteoarthritis-Comparative Review by Electronic Health Record Data Mining and in-Home Visit Verification
Background/Purpose: To compare current utilization of usual nonpharmacologic (NP) and pharmacologic (P) therapies for hand osteoarthritis (OA) by primary care providers (PCPs) and patients (Pts)…Abstract Number: 1139 • 2012 ACR/ARHP Annual Meeting
Inhaled Nitrous Oxide Facilitates Access to Intra-Articular Corticosteroid Injections in Children with Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood affecting 1 in 1000 children. Medical management for arthritis often includes intra-articular…Abstract Number: 1140 • 2012 ACR/ARHP Annual Meeting
Response to Adalimumab in 40 Patients with refractory juvenile Idiopathic Arthritis-Associated Uveitis. A Multicenter Study
Background/Purpose: To assess the efficacy and safety of treatment with adalimumab therapy in patients with refractory Juvenile Idiopathic Arthritis (JIA)-associated uveitis. Methods: Multicenter study on…Abstract Number: 1141 • 2012 ACR/ARHP Annual Meeting
Safety of Celecoxib and Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Juvenile Idiopathic Arthritis
Background/Purpose: Celecoxib, a selective COX-2 inhibitor, was approved by the FDA for the treatment of the signs and symptoms of JIA in children aged 2-17…Abstract Number: 1142 • 2012 ACR/ARHP Annual Meeting
Efficacy of Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review Using Indirect Comparisons
Background/Purpose: During the last decade the availability of biologic agents for the treatment of juvenile idiopathic arthritis (JIA) increased substantially. Because direct head-to-head trials comparing…Abstract Number: 1143 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Therapy in Children with Systemic Onset Juvenile Idiopathic Arthritis. Russian Experience
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is classified as an acquired autoinflammatory disease. The interleukin-1 and interleukin-6 play a pivotal role in pathogenesis of this…Abstract Number: 1144 • 2012 ACR/ARHP Annual Meeting
Phenotypic Characterization of Childhood Onset Rheumatoid Arthritis
Background/Purpose: Rheumatoid Factor positive polyarthritis (RF+ poly) is the JIA subtype that resembles adult seropositive RA. However, the ILAR classification criteria for RF+ polyarthritis do…Abstract Number: 1145 • 2012 ACR/ARHP Annual Meeting
Use of Non-Etanercept Biologics in Children with Juvenile Idiopathic Arthritis: Results From the Biologics for Children with Rheumatic Diseases Study
Background/Purpose: The management of juvenile idiopathic arthritis (JIA) has been revolutionised by the introduction of biologic therapy, although the majority remain unlicensed for children. Until…Abstract Number: 1146 • 2012 ACR/ARHP Annual Meeting
Choice of Systemic JIA Treatment Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) Rheumatologists
Background/Purpose: Despite recent advances in identifying effective treatments for systemic Juvenile Idiopathic Arthritis (sJIA), many pediatric rheumatologists continue to use corticosteroids and methotrexate. The Childhood…Abstract Number: 1147 • 2012 ACR/ARHP Annual Meeting
Definition of Improvement Thresholds in Juvenile Idiopathic Arthritis Using the JADAS
Definition of improvement thresholds in juvenile idiopathic arthritis (JIA) using the JADAS Background/Purpose: Evaluation of disease activity in JIA is fundamental in clinical assessment. The…Abstract Number: 1148 • 2012 ACR/ARHP Annual Meeting
Adalimumab – Effective Control under Refractory JIA Associated Uveitis
Background/Purpose: Treatment of juvenile idiopathic arthritis (JIA)–associated uveitis is one of the serious problems of paediatric rheumatology. JIA associated uveitis often is refractory to MTX,…Abstract Number: 1149 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety of Etanercept in Patients with Juvenile Idiopathic Arthritis (JIA)
Background/Purpose: Etanercept (Eta) has been the most frequently used biologic drug in patients with JIA. In Germany, about one in three patients with polyarticular JIA…
ACR Meeting Abstracts